by Philipp Wenter
AL
Scalable Synthesis Technology
Oligonucleotides are a universal ingredient for molecular biology work- flows such as PCR and qPCR. For most pipelines, scientists need only small amounts of high-quality oligo to use as primers or barcodes. Un- fortunately, the limitations of many conventional synthesis methods preclude oligo manufacturers from producing such small amounts. Instead, they generate significantly more product, requiring research- ers to pay for the excess. A new platform from Eurofins Genomics US (Louisville, KY) can produce much smaller volumes, allowing laboratories to order only the amount of oligo they need.
Technology limits
Since the development of DNA synthesis procedures, there have been tremendous improvements, perhaps most notably the ability to produce smaller volumes. Consistent progress has reduced that lower limit to today’s standard volume of 25 nanomoles, but a typical PCR reac- tion needs just 15 picomoles of DNA. Assuming researchers will run 100 reactions with every set of primers, the current oligo production scale is still an order of magnitude too high. Oligo manufacturers are lim- ited in their ability in this regard. The technical requirements associated with delivering, dispensing, and removing reagents in the synthesis pro- cess are obstacles to continued miniaturization. Conventional synthesis technology appears to have reached a plateau for volume reductions.
Balancing act For end users, the biggest challenge in managing oligo usage is balanc-
ing competing needs in quality, quantity, cost, and turnaround time. Some providers offer ultrasmall volumes for specialty oligos or overnight shipping, but these premium services come at a price. Obviously, cutting corners on quality is unacceptable, as that would invalidate any down- stream results. Since existing DNA synthesis platforms cannot deliver on all of these factors, however, scientists must select which features they can do without.
DNA used for next-generation sequencing applications must have ultra- low error rates and the highest purity levels. To ensure accuracy and reliability, most oligo manufacturers incorporate meticulous quality- control protocols. Many use mass spectrometry to ensure that the base composition of the DNA sent to a customer matches the order, as well as taking other steps designed to meet rigorous manufacturing standards. Additional reporting measures are required to comply with government regulations for DNA that will be used in clinical labs. It is not surprising that all of these quality-control processes—especially those required for clinical use—increase the cost of oligo production.
AMERICAN LABORATORY 31
To keep costs in check, scientists may try to compromise on other factors, such as turnaround time. This is not always possible, though, and users who need materials quickly may have to pay surcharges for rapid shipping. Vendors may also require customized delivery formats such as oligo pools in specific plates or tubes, or ready-to-use formula- tions, which can increase costs. The most important factor in managing costs—deciding how much DNA to order—is not feasible in conven- tional synthesis.
Addressing the oligo challenge At Eurofins Genomics US, the decision was made to address the oligo
volume challenge since this is the most effective way to enable scientists to reduce costs. Company researchers collaborated with a group of aerospace engineers for a fresh perspective on how to achieve this. The pairing made sense, as DNA synthesis incorporates fluidics, air pressure and flow, vibration, and thermodynamics—all important factors in engineering jet engines.
The platform that was a product of this collaboration (Figure 1) delivers high-quality, scalable production volumes and faster manufacturing times. Phosphoramidite chemistry produces coupling efficiencies of bet- ter than 99.5%. Miniaturized reagent dispensing enables fast synthesis reactions. Using the new technology, company scientists can produce as little as 1 nanomole of DNA (or as much as needed). This lower oligo volume meets the need for most PCR or qPCR workflows.
Figure 1 – Eurofins DNA synthesizer.
Philipp Wenter is vice president of Manufacturing and R&D for Eurofins Genomics US, 12701 Plantside Dr., Louisville, KY 40299, U.S.A.; tel.: 1-800-688- 2248; e-mail:
PhilippWenter@eurofins.com;
www.eurofinsgenomics.com
JUNE/JULY 2017
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56